.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Satralizumab is an interleukin-6 receptor blocker developed for neuromyelitis optica spectrum disorder, a relapsing autoimmune CNS disease in which attacks can cause severe visual and spinal disability. In a phase 3 randomized, double-blind trial, satralizumab was added to stable immunosuppressive treatment in patients with NMOSD who were either AQP4-antibody positive or negative. The treatment reduced the risk of protocol-defined relapse, with the clearest benefit in the AQP4-IgG-positive subgroup. This is clinically relevant because NMOSD management aims primarily to prevent attacks; disability may accumulate quickly after severe optic neuritis or myelitis. For HCPs, the trial reinforces the importance of correctly distinguishing NMOSD from multiple sclerosis and other demyelinating disorders before selecting long-term therapy. AQP4 antibody status is therefore not simply descriptive—it can help define the treatment pathway. Satralizumab requires monitoring for infection and other adverse effects and should be integrated into a broader relapse-prevention strategy. The findings are directly aligned with IANCON's neuroimmunology and optic-neuritis themes.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Satralizumab is an interleukin-6 receptor blocker developed for neuromyelitis optica spectrum disorder, a relapsing autoimmune CNS disease in which attacks can cause severe visual and spinal disability. In a phase 3 randomized, double-blind trial, satralizumab was added to stable immunosuppressive treatment in patients with NMOSD who were either AQP4-antibody positive or negative. The treatment reduced the risk of protocol-defined relapse, with the clearest benefit in the AQP4-IgG-positive subgroup. This is clinically relevant because NMOSD management aims primarily to prevent attacks; disability may accumulate quickly after severe optic neuritis or myelitis. For HCPs, the trial reinforces the importance of correctly distinguishing NMOSD from multiple sclerosis and other demyelinating disorders before selecting long-term therapy. AQP4 antibody status is therefore not simply descriptive—it can help define the treatment pathway. Satralizumab requires monitoring for infection and other adverse effects and should be integrated into a broader relapse-prevention strategy. The findings are directly aligned with IANCON's neuroimmunology and optic-neuritis themes.
last month
Preclinical findings demonstrate that ginsenoside Ra1 preserves vascular integrity and attenuates multi-organ injury during sepsis by targeting non-muscle myosin heavy chain IIA (NMMHC IIA) and dampening TLR4/NF-κB/NLRP3 inflammatory signaling.
2 days back
An all-printed immunosensing microchip detects urinary sFlt-1 in just 10 minutes with 3.61 pg/mL sensitivity. By leveraging photonic bandgap engineering, this low-cost, cleanroom-free platform provides non-invasive preeclampsia screening, offering substantial benefits for point-of-care obstetric triage.
2 days back
Wearable ultrasound patches are transforming healthcare by shifting medicine from episodic evaluations to continuous monitoring. Discover how flexible acoustic transducers advance cardiovascular tracking, musculoskeletal imaging, neuromodulation, and on-demand closed-loop theranostics.
2 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
